Abciximab disappoints in ACS without early revascularisation

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1257, 2000-01, pp. : 13-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Abciximab: benefits for some in ACS

Inpharma, Vol. 1, Iss. 1535, 2006-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Abciximab beneficial in younger patients with ACS undergoing PCI

Inpharma, Vol. 1, Iss. 1569, 2007-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Abciximab: A Pharmacoeconomic Review of its Use in Percutaneous Coronary Revascularisation

By Dunn C.J. Foster R.H.

PharmacoEconomics, Vol. 16, Iss. 6, 1999-12 ,pp. : 711-741

Adis International

Access to resources Recommend Favorite

CD40 levels predict benefit from abciximab in ACS

Inpharma, Vol. 1, Iss. 1380, 2003-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Abciximab: An Updated Review of its Therapeutic Use in Patients with Ischaemic Heart Disease Undergoing Percutaneous Coronary Revascularisation

By Ibbotson T. McGavin J.K. Goa K.L.

Drugs, Vol. 63, Iss. 11, 2003-01 ,pp. : 1121-1163

Adis International

Access to resources Recommend Favorite